Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 3—March 2004
Synopsis

Reemerging Leptospirosis, California

Elissa Meites*, Michele T. Jay†, Stanley Deresinski†‡, Wun-Ju Shieh§, Sherif R. Zaki§, Lucy Tompkins*, and D. Scott Smith*¶Comments to Author 
Author affiliations: *Stanford University School of Medicine, Stanford, California, USA; †California Department of Health Services, Sacramento, California, USA; ‡Santa Clara Valley Medical Center, San Jose, California, USA; §Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ¶Kaiser Permanente Medical Group, Redwood City, California, USA

Main Article

Table 2

Acute- and convalescent-phase serologic and microscopy diagnosis of leptospirosis by MAT,a IgM-ELISA, IHA, and IHC assay in California case reportsb

Case Case 1 Case 2 Case 3 Case 4 Case 5
Days post exposure
9
11
15
32
21
36
23
44
Acute
conv
MAT
ND
ND
Neg
1:3200
Neg
1:800
1:800
1:200
Neg
ND
ELISA
ND
ND
Neg
Pos
Pos
ND
Pos
ND
Pos
ND
IHA
1:50
1:800
ND
ND
ND
ND
ND
ND
ND
1:200
IHC assay NA NA NA Pos Pos

aMAT, microagglutination test. Highest MAT titer reported to any leptospira serogroup.
bIgM-ELISA, immunoglobulin M–Enzyme-Linked ImmunoSorbent Assay; IHA, indirect hemagluttination assay; IHC, immunohistochemical; NA: not available; ND: not done.

Main Article

Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external